Holen Sie sich die Stockscreener-App
155.73
0.62%
-0.97
Handel nachbörslich:
156.91
1.18
+0.76%
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
NBIX (NASDAQ: NBIX) broker files Form 144 to sell 3,888 shares - Stock Titan
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June - Yahoo Finance
Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform - Insider Monkey
(NBIX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Neurocrine Biosciences, Inc. (NBIX): Investor Outlook Reveals 22.56% Potential Upside - DirectorsTalk Interviews
Singer Carnie Wilson Finds Strength in Speaking Out on Mental Health Challenges - SELF Magazine
Bernstein Initiates Coverage on Neurocrine Biosciences With Outperform Rating - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential - ChartMill
NBIX Technical Analysis | Trend, Signals & Chart Patterns | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock - Investing.com UK
Director Shalini Sharp converts 1,659 RSUs into NBIX common stock shares - Stock Titan
NBIX (NBIX) director converts 3,318 RSUs into 10,386 common shares - Stock Titan
Neurocrine (NASDAQ: NBIX) director converts 3,318 RSUs to shares - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 3,318 RSUs to stock - Stock Titan
Neurocrine Biosciences (NBIX) director converts 3,318 RSUs into 3,318 shares - Stock Titan
Neurocrine (NBIX) director converts 3,318 RSUs into common shares - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Johanna Mercier (NBIX) converts 3,318 RSUs into Neurocrine Biosciences stock - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 1,659 RSUs to shares - Stock Titan
Bernstein initiates Neurocrine stock with outperform rating on drug potential - Investing.com
Bernstein initiates Neurocrine stock with outperform rating on drug potential By Investing.com - Investing.com Canada
Neurocrine Biosciences stock (US62886E1082): focus on INGREZZA momentum and growth outlook - AD HOC NEWS
Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) Narrative - Yahoo Finance
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention - simplywall.st
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Morgan Stanley lists Rule 144 sale of NBIX shares (NBIX) - Stock Titan
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock By Investing.com - Investing.com Australia
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com UK
Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Neurocrine (NBIX) Reveals Positive Data on INGREZZA for Mild Tar - GuruFocus
Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com South Africa
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com
2.34%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):